MedCity News February 9, 2025
CMS recently issued a statement saying that it’s continuing the Medicare Drug Price Negotiation Program but is leaving the door open for potential changes. Experts weighed in on what changes could be made and what changes they would like to see.
In his first month as president, Donald Trump and his administration have gleefully dismantled many of Former President Joe Biden’s initiatives. However, there has been one notable exception: the Medicare Drug Price Negotiation Program — although they’re leaving room for some potential changes.
The program, created under the Inflation Reduction Act (IRA), allows the federal government to negotiate the prices of some of the costliest Medicare Part D drugs directly with drug companies. The first 10 drugs selected for...
Today's Sponsors
Today's Sponsor